title: Regression and progression in neuroblastoma. Does genetics predict tumour behaviour?
abstract: Neuroblastoma (NB) is a heterogeneous disease. The clinical course may range from spontaneous regression and maturation to very aggressive behaviour. Stage 4s is a unique subcategory of NB, generally associated with good prognosis, despite skin and/or liver involvement and the frequent presence of tumour cells in the bone marrow. Another type of NB is the locally invasive tumour without bone and bone marrow involvement which can also have a good prognosis, irrespective of lymph node involvement. Unfortunately, there is only limited biological information on such tumours which have not been treated with cytotoxic therapy despite lymph node involvement, residual tumour mass after surgery and/or bone marrow infiltration. In order to find specific genetic changes common to NBs with a benign clinical course, we studied the genetic abnormalities of these tumours and compared them with highly aggressive tumours. We analysed a series of 54 localised and stage 4s tumours by means of in situ hybridisation performed on fresh cells or on paraffin embedded tissues. In addition, we performed classical cytogenetics, Southern blotting and PCR analysis on fresh tumour tissue. The majority of patients had been treated with surgery alone, and in a number of patients tumour resection was incomplete. Deletions at 1p36 and amplifications of the MYCN oncogene were absent, and diploidy or tetraploidy were not seen in any case, with residual localised tumours possessing a favourable outcome. Unexpectedly, one patient with a tetraploid 4s tumour without any genetic structural changes not receiving any cytotoxic treatment, did well. Interestingly, this genetic spectrum contrasted with that of progressing tumours, in which most had genetic aberrations, the deletion at 1p36 being the most common event. These data, although limited, suggest that an intact 1p36 (recognised by D1Z2), the absence of MYCN amplification and near-triploidy (at least in localised tumours), represent prerequisites for spontaneous regression and/or maturation.
authors.affiliation: CCRI, St Anna Kinderspital, Vienna, Austria.
authors.forename: P F
authors.initials: PF
authors.lastname: Ambros
authors.forename: I M
authors.initials: IM
authors.lastname: Ambros
authors.forename: S
authors.initials: S
authors.lastname: Strehl
authors.forename: S
authors.initials: S
authors.lastname: Bauer
authors.forename: A
authors.initials: A
authors.lastname: Luegmayr
authors.forename: H
authors.initials: H
authors.lastname: Kovar
authors.forename: R
authors.initials: R
authors.lastname: Ladenstein
authors.forename: F M
authors.initials: FM
authors.lastname: Fink
authors.forename: E
authors.initials: E
authors.lastname: Horcher
authors.forename: G
authors.initials: G
authors.lastname: Printz
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002869:Chromosome Aberrations; D018450:Disease Progression; D005784:Gene Amplification; D016259:Genes, myc; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007223:Infant; D009365:Neoplasm Regression, Spontaneous / Q000235:genetics*; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000235:genetics* / Q000473:pathology / Q000556:secondary; D011003:Ploidies